Gritstone Oncology (Nasdaq:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GRANITE-001 for the treatment of colorectal cancer. As quoted in the press release: GRANITE-001 is a personalized immunotherapy containing patient-specific … Continued
The post Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001 appeared first on Investing News Network.
Original Article: Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001